AcelRx Pharmaceuticals (ACRX) Stock Downgraded at Piper

AcelRx Pharmaceuticals Inc (ACRX) was downgraded to ‘Neutral’ from ‘Overweight’ at Piper Jaffray, citing the FDA’s rejection of the company’s pain drug device, Zalviso, late on Friday. Piper lowered its price target for the pharma company shares to $8 from $14. ACRX closed yesterday at $6.39 on volume of 15.7 million shares, nearly 15 million […] View the full post at: AcelRx Pharmaceuticals (ACRX) Stock Downgraded at Piper Related posts: Caterpillar Inc. Downgraded to “Neutral” at BofA S&P Cuts Greece to Junk, Portugal Also Downgraded Pre-Market Earnings (May 3)